Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (VERITAS)

The main objective is to evaluate the efficacy of two intensified consolidation strategies in very-high risk neuroblastoma (VHR-NBL) patients in terms of event-free survival from randomisation date. This evaluation will follow a hierarchical testing procedure: each experimental treatment will be first evaluated as a single-arm phase 2 study, and in …

  • 5 views
  • 27 Feb, 2022
  • 2 locations
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (COSI)

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults. In the last decade the use of …

remission
blast cells
thiotepa
cell transplantation
cytarabine
  • 0 views
  • 02 Mar, 2022
  • 1 location
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Pharmacogenomics (PG) offers the opportunity to individualize treatment according to patient genetic variations which influence activity of enzyme metabolizing or acting in the pathway of prescribed chemotherapy drugs. This add-on research aims to prospectively investigate variations in several candidate genes related to all types of chemotherapeutic drugs and TBI used …

remission
chemotherapy drug
cancer
b-cell acute lymphoblastic leukemia
lymphoid leukemia
  • 17 views
  • 23 Jan, 2021
  • 8 locations
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

  • 17 views
  • 12 May, 2022
  • 17 locations
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking …

catecholamines
mycn protein
high-risk neuroblastoma
ganglioneuroblastoma
melphalan
  • 117 views
  • 01 Mar, 2022
  • 102 locations
TEAM (Thiotepa Etoposide Cytosar Melphalan ) for AutoSCT in Lymphoma

Study is designed to explore whether the introduction of Thiotepa, to the pre autologous stem-cell transplantation (ASCT) conditioning will reduce toxicity and thus improve outcome following

etoposide
hodgkin's disease
thiotepa
cell transplantation
melphalan
  • 0 views
  • 25 Jan, 2021
  • 1 location
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

In the United States, thiotepa has been utilized in reduced intensity conditioning regimens for alternative donor courses (double umbilical cord blood transplant (dUCBT) and haplo-identical

remission
myelodysplastic syndromes
intrathecal chemotherapy
hematologic malignancy
hodgkin's disease
  • 12 views
  • 22 Mar, 2022
  • 1 location
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

This phase II clinical trial studies how well treosulfan, thiotepa, fludarabine, and rabbit anti-thymocyte globulin (rATG) before donor stem cell transplantation works in treating patients with

primary cancer
treatment regimen
bone marrow procedure
  • 0 views
  • 29 Apr, 2022
  • 1 location
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin

nervous
germ cell tumor
wilms' tumor
pnet
metastasis
  • 209 views
  • 04 May, 2022
  • 1 location
Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow (TRANSFORM)

-matched related donors. Preparation before transplant includes the chemotherapy drugs hydroxyurea, fludarabine, thiotepa, anti-thymocyte globulin, and cyclophosphamide. It also includes radiation.

asthma
sickle cell trait
hydroxyurea
anti-thymocyte globulin
hemoglobinopathy
  • 33 views
  • 09 Apr, 2022
  • 1 location